This Florida Lab Collected Millions From Medicare Genetic Tests, but Its Sudden Disappearance Raises Questions

A relatively obscure clinical laboratory operating from a small office complex in Deerfield Beach, Florida, became one of the most striking names in Medicare’s rapidly expanding genetic-testing business. Reliable Results Labs, often shortened to R&R Labs, was registered as a clinical medical laboratory at 600 Fairway Drive, Suite 104. On paper, it looked like one of many independent diagnostic labs scattered across South Florida. Medicare billing data, however, shows that the company was collecting sums normally associated with far larger healthcare organizations. In 2024 alone, Medicare paid Reliable Results Labs approximately $32.4 million for more than 50,000 services provided to about 4,800 beneficiaries. A large portion of that money came from expensive genetic tests, some of which Medicare reimbursed at thousands of dollars for a single test. One of the most eye-catching procedures was CPT 81419, a genetic panel used to evaluate genes associated with epilepsy. The test is expensive. Medicare reimbursement has been roughly $2,400 per test, meaning even a relatively small number of claims can generate millions of dollars in government spending. Reliable Results Labs became one of Florida’s largest billers for that procedure. Medicare data for 2023 shows the lab performed 621 epilepsy gene panels, more than any other Florida provider listed in that year’s data. By 2024, its volume had increased dramatically to roughly 2,739 epilepsy-panel services. At approximately $2,400 apiece, those 2024 epilepsy tests alone represented about $6.6 million in Medicare payments. And epilepsy testing was only part of the lab’s genetic-testing business. Reliable Results Labs also billed heavily for CPT 81440, a genetic sequencing test involving mitochondrial disorders. Medicare paid roughly $3,256 for each of the lab’s 2,787 services under that code in 2024, representing more than $9 million in payments. The lab also performed thousands of panels involving severe inherited conditions, hereditary disorders of the peripheral nervous system, metabolic disorders and other genetic diseases. Taken together, those claims helped push Reliable Results Labs to more than $32 million in Medicare fee-for-service revenue during a single year. That figure becomes especially interesting when placed within a much larger national trend. Medicare spending on genetic testing has exploded in recent years. The Department of Health and Human Services Office of Inspector General reported that Medicare Part B spent $8.4 billion on clinical laboratory tests in 2024. Genetic tests represented only about 5 percent of paid lab tests, yet they accounted for approximately $3.6 billion, or 43 percent of all Medicare Part B laboratory spending. Federal officials have become increasingly concerned about that imbalance. Some of the fastest-growing codes have involved tests that appear unusual for the Medicare population. Epilepsy genetic panels are one example. These tests can have legitimate medical uses, particularly when doctors are trying to determine whether seizures may be caused by an inherited disorder. Genetic testing can be especially valuable for children and younger patients with unexplained epilepsy. Medicare, however, overwhelmingly serves people age 65 and older. That does not mean an older Medicare patient could never require an epilepsy gene panel. It does mean that extremely rapid growth in spending on expensive inherited-disease tests has attracted scrutiny from healthcare-policy researchers and federal regulators. Medicare payments for CPT 81419 grew from less than $100,000 nationally in 2022 to tens of millions of dollars only two years later. Researchers examining the claims noticed that much of the billing was concentrated among a relatively small group of laboratories in Florida, Texas, New Jersey and other states covered by particular Medicare administrative contractors. Reliable Results Labs was one of those laboratories. Its 2024 claims were remarkable not simply because of epilepsy testing. The laboratory billed for a wide collection of expensive genetic panels, helping it generate an average of roughly $640 in Medicare revenue for every service reported in the public dataset. That was dramatically higher than the national average across laboratory services. The company itself was relatively new. Reliable Results Labs Inc. was incorporated in Florida in February 2023. The organization received its National Provider Identifier the following month and registered as a clinical medical laboratory. Its official NPI was 1639879034, and Ralph J. DeLuca III was listed as the company’s president and authorized official. The address was Suite 104 at 600 Fairway Drive, part of the Hillsboro Executive Center office complex near Interstate 95 in Deerfield Beach. Within approximately a year of registering, the laboratory was receiving tens of millions of dollars from Medicare. That rapid rise is one reason the company has attracted attention from people examining public healthcare-spending data. There have also been complaints involving the lab’s name. In 2025, a complaint submitted to the Better Business Bureau’s Scam Tracker described an elderly Medicare beneficiary who allegedly received an unexpected laboratory order connected to R&R Labs after a suspicious telephone call. The complainant claimed that personal Medicare information had been used without authorization. That report is an allegation submitted by an individual, not a government finding against Reliable Results Labs. There is currently no publicly identified criminal conviction establishing that the laboratory itself committed Medicare fraud, and a consumer complaint should not be treated as proof that it did. Still, the complaint exists alongside a broader federal concern about aggressive and potentially improper genetic-testing billing. CMS has increasingly focused on laboratories billing large amounts for genetic tests. In 2026, the agency specifically identified genetic and molecular testing as an area vulnerable to fraud, waste and abuse. CMS said its Fraud Defense Operations Center had already helped stop more than $100 million connected to suspect laboratory activity. That makes Reliable Results Labs an interesting case study because its billing profile sits directly inside the category regulators are now examining. There is one important complication to the idea that R&R Labs simply “shut down.” Current public records do not clearly support that conclusion. As of October 2026, Reliable Results Labs still has an active Florida corporation registration. Its NPI remains active in the federal provider registry. Even more significantly, the company currently maintains a functioning website advertising genetic and diagnostic testing from the same 600 Fairway Drive address. The website lists services including pharmacogenomic testing, neurodegenerative testing, hereditary metabolic disorder testing, cardiopulmonary genetic testing and other panels. It also lists regular business hours and describes the laboratory as CLIA and COLA certified. So although there may have been reports that the operation closed or became unreachable at some point, publicly available records currently show an organization that still presents itself as operating. That distinction matters. A sudden drop in Medicare billing would not necessarily mean a business permanently closed. A laboratory could stop billing certain codes, change insurers, suspend operations temporarily, change ownership, lose access to a particular reimbursement pathway or simply continue operating with a different mix of testing. Likewise, millions of dollars in Medicare payments do not necessarily represent company profit. A laboratory receiving $32 million still has equipment, staff, reagents, rent, processing, transportation, compliance and other expenses. What makes Reliable Results Labs unusual is not simply that it made money. It is the combination of its small physical footprint, extremely rapid rise, enormous Medicare reimbursement totals and heavy use of genetic codes that federal regulators have increasingly identified as high risk. The epilepsy numbers are particularly dramatic. In 2023, Reliable Results Labs was listed as Florida’s largest Medicare biller of the epilepsy genetic panel in available provider-level data, performing 621 tests. By 2024, that number had grown to approximately 2,739 tests, enough to generate roughly $6.6 million from that single procedure. Meanwhile, Medicare’s national spending on the same epilepsy test exploded. The laboratory therefore sits at the center of a much bigger mystery about how Medicare genetic testing went from a relatively small expense to a multibillion-dollar industry in only a few years. Federal regulators are now trying to understand that growth. Reliable Results Labs remains an especially striking example: a small Deerfield Beach laboratory that appeared in 2023 and, almost immediately, began receiving tens of millions of dollars from Medicare. Whether the company ultimately becomes part of any enforcement case is not established. What is already documented is remarkable enough. A laboratory operating from Suite 104 of a South Florida office complex became one of the country’s most notable billers of expensive genetic testing, receiving more than $32 million from Medicare in 2024 alone.